Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
NeoGenomics: Strong Revenue Growth and Strategic Initiatives Underpin Buy Rating Amidst Management Changes
Benchmark Co. Maintains NeoGenomics(NEO.US) With Hold Rating
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $19 to $19
NeoGenomics: Balancing Promising Growth Prospects With Market Uncertainties and Valuation Concerns
Express News | Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
NeoGenomics Analyst Ratings
Cutting-Edge Cancer Therapies Lead the Way Into a Transformative Year
Sector Update: Health Care Stocks Rise Premarket Wednesday
Craig-Hallum Sticks to Its Buy Rating for NeoGenomics (NEO)
NeoGenomics Announces Executive Bonuses and Revenue Growth
NeoGenomics Provides 2025 Revenue Outlook
NeoGenomics Shares Are Trading Higher Following Strong FY25 Guidance.
Express News | Neogenomics Inc FY2025 Rev View $727.7 Mln -- LSEG IBES Data
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
Express News | Neogenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains?
Analysts' Top Healthcare Picks: ScPharmaceuticals (SCPH), NeoGenomics (NEO)
NeoGenomics Management to Meet With Piper Sandler